



## CYFLUENT REAL WORLD TEST RESULTS-B6

Plan Report ID Number:

Developer Name: Cyfluent

Product Name(s): Cyfluent

Version Number(s): 3.2.9

Certified Health IT Product List (CHPL) ID(s): 0015ET7SML1PUC3

Developer Real World Testing Plan Page URL: [https://www.cyfluentphr.com/ Files/CURES/](https://www.cyfluentphr.com/Files/CURES/)

## SUMMARY OF TESTING METHODS AND KEY FINDINGS

Case management logs and system logs have been reviewed and ensured the export function is operating properly and determined the frequency of use. Log files obtained during Real World Testing were used for analysis in several areas to validate the proper operation of the export. This test methodology primarily tested the conformance of the implementation.

Testing was conducted using client data and synthetic data due to lack of a client transmitting to cancer registries and public health agencies at this time.

## STANDARDS UPDATES (INCLUDING STANDARDS VERSION ADVANCEMENT PROCESS (SVAP) AND UNITED STATES CORE DATA FOR INTEROPERABILITY (USCDI))

Products certified with voluntary SVAP or USCDI standards.

Standard (and version)	All standards versions are those specified in USCDI v1. The developer used SVAP to update its (e)(1) module to support the new version of the Direct transport protocol (now known as Secure Health Transport) during the testing period.
------------------------	---



## CARE SETTING(S)

- Ambulatory Care

## METRICS AND OUTCOMES

---

### CRITERIA AND ASSOCIATED CRITERIA, METRIC, OUTCOMES AND CHALLENGES

- **§ 170.315(b)(6) Data export –**
  - *Metric:* % Creation of export summaries
  - *Outcome:* 100 % Successful creation of export summaries for specified patient groups in correct formatting. Authorized users able to share EHI for a patient population using the export function.
- **§ 170.315(b)(9) Care plan**
  - *Measurement:* % Record, change, access, create, receive of Care Plans;
  - *Outcome:* 100% success
  - *Challenges:* low usage, therefore testing was performed using synthetic data in addition to client data
- **§ 170.315(g)(7) Application access— patient selection**
  - *Measurement:* % Receive, identify, return token and document
  - *Outcome:* 100% success
- **§ 170.315(g)(8) Application access— data category request**
  - *Measurement:* % respond and document requests
  - *Outcome:* 100% successful
- **§ 170.315(g)(9) Application access— all data request**
  - *Measurement:* % respond to request, document
  - *Outcome:* 100% successful
- **§ 170.315(g)(10) Standardized API for patient and population services**
  - *Measurement:* % of single/multiple patient data request
  - *Outcome:* 100% successful
- **§170.315 (f)(4): Transmission to Cancer Registries**
  - *Measurement:* % create and transmit
  - *Outcome:* 100% successful
  - *Challenges:* No client using this functionality at this time, therefore testing was performed using synthetic data
- **§170.315 (f)(5) Transmission to public health agencies – electronic case reporting**
  - *Measurement:* % Consume, maintain, and determine reportability, create and transmit
  - *Outcome:* 100% successful
  - *Challenges:* No client using this functionality at this time, therefore testing was performed using synthetic data



## KEY MILESTONES

Key Milestone	Care Setting	Date/Timeframe
Release of documentation for the Real-World Testing to be provided to authorized representatives and providers. This includes surveys, specific instructions on what to look for, how to record issues encountered, and Customer Agreements.	Ambulatory Care	<i>December 2022</i>
Collection of information as laid out by the plan for the period.		<i>January 2023</i>
Planned System updates to allow for collection data after a SVAP update		<i>February 2023</i>
Follow-up with the providers and authorized representatives to understand any issues arising with the data collection.		<i>Quarterly 2023</i>
End of Real World Testing period/final collection of all data for analysis		<i>January 2024</i>
Analysis and report creation		<i>January 2024</i>
Submit Real World Testing report to ACB (Drummond)		<i>February 2024</i>

## ATTESTATION

This Real World Testing Results report is complete with all required elements, including measures that address all certification criteria and care settings. All information in this plan is up to date and fully addresses the health IT developer's Real World Testing requirements.

Authorized Representative Name: Gopianand Vasudevan

Authorized Representative Email: gvasudevan@plan-sys.com

Authorized Representative Phone: (703) 578-6641

Authorized Representative Signature:   
Gopianand Vasudevan (Jan 22, 2024 14:27 EST)

Date: 1/22/2024

# Cyfluent Real World Test Results\_b6\_2023

Final Audit Report


2024-01-22

Created:	2024-01-22
By:	Gwen Thomas (gthomas@plan-sys.com)
Status:	Signed
Transaction ID:	CBJCHBCAABAAG2CD3KG8wYO3falrmKRg-Tcq5DBM8hal


## "Cyfluent Real World Test Results\_b6\_2023" History

 Document created by Gwen Thomas (gthomas@plan-sys.com)

2024-01-22 - 7:22:52 PM GMT- IP address: 40.85.182.177

 Document emailed to gvasudevan@plan-sys.com for signature

2024-01-22 - 7:23:26 PM GMT

 Email viewed by gvasudevan@plan-sys.com

2024-01-22 - 7:27:19 PM GMT- IP address: 104.47.74.126

 Signer gvasudevan@plan-sys.com entered name at signing as Gopianand Vasudevan

2024-01-22 - 7:27:46 PM GMT- IP address: 50.238.112.3

 Document e-signed by Gopianand Vasudevan (gvasudevan@plan-sys.com)

Signature Date: 2024-01-22 - 7:27:48 PM GMT - Time Source: server- IP address: 50.238.112.3

 Agreement completed.

2024-01-22 - 7:27:48 PM GMT